الفهرس 
Table of ContentsOnly 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
Ankylosing Spondylitis which is considered a sero (-ve) prototype of spondyloarthritis (SpA), is a chronic rheumatic auto-inflammatory disease. AS is characterized by presence of inflammatory back pain, sacroiliitis, enthesitis, peripheral arthritis and anterior uveitis. Ultimately, AS can result in mental and economic burdens in these cases, their families and the general public. Consequently, it is significant to discover a possible bio-marker for monitoring the activity of the disease and development of better approaches for its prevention and management. Previous studies have revealed the Sema 3A implication in skeleton. Osteoblast [OB] osteoclast [OC], and osteocyte express Semaphorin 3A and its receptors. Semaphorin 3A can lead to inhibition of the OC precursor cells migration by suppressing the activation of RhoA. Contrariwise, differentiation of OB is encouraged by Semaphorin 3A via the canonical Wingless (WNT)/β-catenin pathway activation. Additionally, Semaphorin 3A is known as a regulator in the immune responses, from the early beginning to the late subsidence phase of inflammation. The expression of Sema 3A has been detected high in activated T cells and differentiating macrophages, signifying that it plays a role in modifying inflammatory conditions. This study was conducted at Mansoura university hospitals aiming to measure serum Semaphorin 3A in AS patients and to investigate any correlations with disease parameters, activity, function and treatment. We included a total of 30 cases diagnosed with ankylosing spondylitis who fulfilled the 1984 modified NewYork criteria. In addition, 30 age and sex matched control subjects were also included.